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A total of 1,021 extended-spectrum--lactamase-producing Escherichia coli (ESBLEC) isolates obtained in 2006 during a Span-
ish national survey conducted in 44 hospitals were analyzed for the presence of the O25b:H4-B2-ST131 (sequence type 131)
clonal group. Overall, 195 (19%) O25b-ST131 isolates were detected, with prevalence rates ranging from 0% to 52% per hospital.
Molecular characterization of 130 representative O25b-ST131 isolates showed that 96 (74%) were positive for CTX-M-15, 15
(12%) for CTX-M-14, 9 (7%) for SHV-12, 6 (5%) for CTX-M-9, 5 (4%) for CTX-M-32, and 1 (0.7%) each for CTX-M-3 and the
new ESBL enzyme CTX-M-103. The 130 O25b-ST131 isolates exhibited relatively high virulence scores (mean, 14.4 virulence
genes). Although the virulence profiles of the O25b-ST131 isolates were fairly homogeneous, they could be classified into four
main virotypes based on the presence or absence of four distinctive virulence genes: virotypes A (22%) (afa FM955459 positive,
iroN negative, ibeA negative, sat positive or negative), B (31%) (afa FM955459 negative, iroN positive, ibeA negative, sat positive
or negative), C (32%) (afa FM955459 negative, iroN negative, ibeA negative, sat positive), and D (13%) (afa FM955459 negative,
iroN positive or negative, ibeA positive, sat positive or negative). The four virotypes were also identified in other countries, with
virotype C being overrepresented internationally. Correspondingly, an analysis of XbaI macrorestriction profiles revealed four
major clusters, which were largely virotype specific. Certain epidemiological and clinical features corresponded with the viro-
type. Statistically significant virotype-specific associations included, for virotype B, older age and a lower frequency of infection
(versus colonization), for virotype C, a higher frequency of infection, and for virotype D, younger age and community-acquired
infections. In isolates of the O25b:H4-B2-ST131 clonal group, these findings uniquely define four main virotypes, which are in-
ternationally distributed, correspond with pulsed-field gel electrophoresis (PFGE) profiles, and exhibit distinctive clinical-epide-
miological associations.
In recent years, extended-spectrum -lactamase (ESBL) produc-tion in Enterobacteriaceae, particularly Escherichia coli, has sig-
nificantly increased in many countries, including Spain (1). In
2000, the first nationwide study of ESBL-producing E. coli
(ESBLEC) in Spain was developed (GEIH-BLEE-2000) (2). The
overall prevalence of ESBL production was 0.5%, with CTX-M-9,
SHV-12, andCTX-M-14 predominating.NoCTX-M-15-produc-
ing E. coli isolates were detected. In contrast, in 2006, a similarly
designed nationwide study (GEIH-BLEE-2006) showed that in
just 6 years, the prevalence of ESBLEC in Spain had increased
8-fold, to 4% (3, 4). In the 2006 study, it was found that CTX-
M-15 had joined CTX-M-14, SHV-12, and CTX-M-9 as a preva-
lent ESBL type. Thus, the predominant ESBL type had changed
quickly, primarily due to the introduction and dissemination of a
single clonal group characterized by CTX-M-15, serotype O25b:
H4, phylogenetic group B2, and sequence type 131 (ST131), i.e.,
the international O25b:H4-B2-ST131 clonal group (5–9).
Unlike most other antimicrobial-resistant E. coli isolates, most
of which derive from non-B2 phylogenetic groups (i.e., A, B1, and
D) but are similar to other group B2 clonal groups, O25b:H4-B2-
ST131 E. coli isolates typically exhibit multiple virulence factors,
including adhesins, toxins, siderophores, and group 2 capsules.
Thus, this clonal group combines both resistance and virulence
genes, which in classical extraintestinal pathogenicE. coli (ExPEC)
isolates have been mutually exclusive (6, 10–14).
In the report of the GEIH-BLEE-2006 study isolates (4), only
the 37CTX-M-15-positive isolates were screened forO25b-ST131
status, and all but five corresponded to this clonal group; the vir-
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ulence genotypes of the O25b-ST131 isolates were not assessed.
Here, we screened all 1,021 ESBLEC isolates from the GEIH-
BLEE-2006 study for O25b-ST131 status and investigated a subset
of the detected O25b-ST131 isolates for virulence genotypes and
pulsed-field gel electrophoresis (PFGE) profiles. The main objec-
tive was to characterize the virulence profile diversity of the ESBL-
producingE. colihumanO25b-ST131 isolates fromSpain, thereby
identifying prominent virotypes. Secondarily, we screened for
these virotypes among ST131 isolates from other countries and
sought to find associations between individual virotypes and epi-
demiological and clinical features.
MATERIALS AND METHODS
Bacterial isolates. Forty-four hospitals representing all Spanish regions
participated in the GEIH-BLEE-2006 project. During the study period (1
February to 30 March 2006), 1,021 ESBL isolates were obtained from
clinical samples (4). Species identification was performed with the API
20E system (bioMérieux, Marcy l’Etoile, France). ESBL production was
confirmed by broth microdilution according to the CLSI guidelines (15).
For comparison, 52 international O25b:H4-B2-ST131 isolates (50 of
human and 2 of avian origin), representing eight countries and three
continents and taken from the reference collections of Nicolas-Chanoine
et al. (6) and Johnson et al. (16), were analyzed to detect globally spread
clonal variants in Spain. These isolates included the most prevalent
ST131-associated XbaI pulsotypes (800, 812, 905, and 968) and others
(699, 788, 797, 806, 903, 904, 909, 910, 911, 913, 915, 916, 917, 919, 979,
981, 1160, 1201, and 1202), as previously described by Johnson et al. (16).
Identification of O25b:H4-B2-ST131 isolates: serotyping, phyloge-
netic grouping, and multilocus sequence typing. The 1,021 Spanish
study isolates were screened using a triplex PCR that was previously de-
veloped for the presumptive identification of O25b-ST131 isolates (5).
Presumptive O25b-ST131 isolates were confirmed as O25:H4 by serotyp-
ing, using type-specific O and H antisera. The major E. coli phylogenetic
group was determined by triplex PCR (17). Multilocus sequencing typing
(MLST) relied on a sequence analysis of seven housekeeping genes (adk,
fumC, gyrB, icd, mdh, purA, and recA) according to the protocol and
primers that are specified on the E. coli MLST website (http://mlst.ucc.ie
/mlst/dbs/Ecoli) (18).
Antibiotic susceptibility testing and molecular characterization of
resistance mechanisms.MICs were determined by the MicroScanWalk-
Away automated system (Siemens, Spain), used according to the manu-
facturer’s instructions, and were interpreted as specified by the CLSI (15).
ESBL production was screened for by using cephalosporin resistance and
the double-disk synergy test. ESBL genotype was determined by PCR us-
ing published TEM-, SHV-, CTX-M-1-, and CTX-M-9-group-specific
primers (19). The resistance genes blaOXA-1 and aac(6=)-Ib-cr were de-
tected by PCR screening and bidirectional sequencing of amplicons (10).
The genetic environment of blaCTX-M-15 was investigated by a specific
PCR for upstream insertion elements (ISEcp1 and IS26) in isolates of
clone O25b-ST131 (20).
Virulence genotyping. The detection of 40 ExPEC-associated viru-
lence genes was done by multiplex PCR (21, 22). The genes we sought to
detect included fimH, fimAvMT78, F10 papA, papA, papC, papEF (positive
isolates were tested for the papG I, papG II, and papG III alleles), sfa/focDE
(positive isolates were tested for sfaS and focG), afa/draBC, afa operon
FM955459, iha, bmaE, gafD, sat, cdtB, cnf1, hlyA, iucD, iutA, iroN, fyuA,
chuA, kpsM II (with itsneuC-K1,K2, andK5 variants), kpsMT III, cvaC, iss,
traT, ibeA, malX, usp, tsh, and ompT (Table 1). Isolates were classified as
ExPEC if they carried 2 of papEF (P fimbriae), sfa/focDE (S/F1C fim-
briae), afa/draBC (Afa/Dr adhesins), iutA (aerobactin receptor), and
kpsM II (group 2 capsule synthesis) (23). The virulence score was the
number of virulence genes that were detected in an isolate. PCR screening
of the fimB insertion sequence (ISL3-like transposase) was performed as
described elsewhere (24). Investigation of the fim operon sequence in the
E. coli EC958 ST131 strain revealed a 1,895-bp insertion in the fimB gene,
which encodes the FimB recombinase that switches on the expression of
type 1 fimbriae (24).
fimH subtyping. The fimHTR allele was identified based on sequence
variation in the E. coli type-1 fimbrial adhesion gene (positions 64 to 552).
Amplification and sequencing were performed as previously described
(25).
Pulsed-field gel electrophoresis. XbaI PFGE analysis was performed
as previously described (21). Profiles were analyzedwith the BioNumerics
fingerprinting software (Applied Maths, St-Martens-Latem, Belgium).
Cluster analysis of the Dice similarity indices based on the unweighted-
pair group method using average linkages (UPGMA) was done to gener-
ate a dendrogram describing the relationship among the PFGE profiles.
Epidemiological and clinical features. Epidemiological and clinical
features were collected by using a structured questionnaire based on the
following data: age, sex, health care environment, underlying conditions,
invasive procedures performed during the preceding week, antimicrobial
use during the preceding month, whether the isolate represented coloni-
zation or infection (and, if infection, the type of infection), and outcome.
Isolates were classified as nosocomially acquired (NA) if obtained 48 h
after hospital admission, as health care-associated (HCA) if the patient
had been admitted to an acute or long-term care center or had received
hemodialysis, specialized home care, or day hospital care during the pre-
ceding 3 months, and as community-acquired (CA) if none of these ap-
plied. The ethics committee of each participating center approved the
study.
Statistical analysis. Comparisons of proportions and scores were
tested using Fisher’s exact test, chi-square test, and the Mann-Whitney U
test, as appropriate. The criterion for statistical significance was set at a P
value of0.05.
Nucleotide sequence accession number. The sequence for the CTX-
M-103 gene was deposited in EMBL under accession number HG423149.
RESULTS
Prevalence and distribution of the O25b:H4-B2-ST131 clonal
group.According to PCR-based detection, theE. coliO25b-ST131
clonal group accounted for 195 (19%) of the 1,021 ESBLEC iso-
lates from the Spanish GEIH-BLEE-2006 project. The O25b-
ST131 isolates were widely distributed across Spain and were re-
covered from 30 of the 44 participating hospitals, including in 13
of the 17 autonomous communities. By hospital, the prevalence of
ST131 among the local ESBL study isolates ranged from 0% to
52% (see Table S1 in the supplemental material), with the highest
values observed in Madrid and the Canary Islands (Fig. 1).
ESBL enzymes produced by O25b:H4-B2-ST131 isolates.
From the 195 total O25b-ST131 isolates, 130 (a maximum of 10
per hospital) were selected randomly for further characterization.
Of these, 96 (74%) were positive for CTX-M-15, 15 (12%) for
CTX-M-14, 9 (7%) for SHV-12, 6 (5%) for CTX-M-9, and 5 (4%)
for CTX-M-32, with the remaining two isolates being positive,
respectively, for CTX-M-3 and a new ESBL enzyme, CTX-M-103,
which was first detected in this study. CTX-M-103 (EMBL acces-
sion no. HG423149) has a single amino acid change compared to
CTX-M-15 and CTX-M-3, and it may be grouped in cluster CTX-
M-1 (26). Three O25b-ST131 isolates from three different hospi-
tals in the Galicia autonomous community exhibited both CTX-
M-14 andCTX-M-15 (Fig. 1; see alsoTable S1 in the supplemental
material).
Virulence genes and virotypes of O25b:H4-B2-ST131 iso-
lates.Of the 40 studied ExPEC-associated virulence genes, 13were
detected by PCR in a majority of the 130 selected O25b-ST131
isolates (Table 1). These 13 genes included fimH (in 99%), F10
papA (77%), iha (75%), sat (76%), iucD (93%), iutA (94%), fyuA
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TABLE 1 Comparison of virulence gene prevalences of 130 representatives of O25b:H4-B2-ST131 ESBLEC isolates in relation to their virotypes
Virulence gene
Isolates in virotype:a
O25b-ST131
isolates PbA B C D
Total no. 29 40 41 17 130
Adhesins (no. [%])
fimH 29 (100) 40 (100) 40 (98) 17 (100) 129 (99)
ISL3-like in fimB 29 (100) 40 (100) 41 (100) 0 110 (85) 0.001
fimAvMT78 0 0 0 1 (6) 1 (1)
F10 papA 27 (93) 31 (78) 41 (100) 0 100 (77) 0.001
papA 0 0 0 12 (71) 12 (9) 0.001
papC 0 0 2 (5) 9 (53) 11 (8) 0.001
papEF 0 0 0 12 (71) 12 (9) 0.001
papG I 0 0 0 0 0
papG II 0 0 0 0 0
papG III 0 0 0 12 (71) 12 (9) 0.001
sfa/focDE 0 0 0 0 0
sfaS 0 0 0 0 0
focG 0 0 0 0 0
afa/draBC 29 (100) 0 1 (2) 0 30 (23) 0.001
afa FM955459 29 (100) 0 0 0 29 (22) 0.001
iha 27 (93) 29 (73) 41 (100) 0 98 (75) 0.001
bmaE 0 0 0 0 0
gafD 0 0 0 0 0
Toxins (no. [%])
sat 28 (97) 30 (75) 41 (100) 0 99 (76) 0.001
cdtB 0 0 0 5 (29) 5 (4) 0.001
cnf1 0 0 0 10 (59) 10 (8) 0.001
hlyA 0 0 0 10 (59) 10 (8) 0.001
Siderophores (no. [%])
iucD 27 (93) 39 (98) 41 (100) 13 (76) 121 (93)
iutA 28 (97) 40 (100) 41 (100) 13 (76) 122 (94)
iroN 0 40 (100) 0 13 (76) 53 (41) 0.001
fyuA 29 (100) 40 (100) 41 (100) 17 (100) 130 (100)
chuA 29 (100) 40 (100) 41 (100) 17 (100) 130 (100)
Capsula (no. [%])
kpsM II 29 (100) 31 (78) 28 (68) 17 (100) 106 (82)
kpsM II-K2 29 (100) 0 0 0 29 (22) 0.001
kpsM II-K5 0 31 (78) 28 (68) 15 (88) 75 (58) 0.001
neuC-K1 0 0 0 2 (12) 2 (2)
kpsM III 0 0 0 0 0
Miscellaneous (no. [%])
cvaC 0 1 (3) 0 9 (53) 10 (1) 0.001
iss 0 39 (98) 0 16 (94) 55 (42) 0.001
traT 21 (72) 21 (53) 36 (88) 16 (94) 96 (74)
ibeA 0 0 0 17 (100) 17 (13) 0.001
malX (PAI) 29 (100) 40 (100) 41 (100) 17 (100) 130 (100)
usp 29 (100) 40 (100) 41 (100) 17 (100) 130 (100)
tsh 0 0 0 0 0
ompT 29 (100) 40 (100) 41 (100) 17 (100) 130 (100)
ExPEC status (no. [%]) 29 (100) 31 (78) 28 (68) 17 (100) 106 (82)
Range of virulence genes
(no.)
10–15 11–17 12–14 9–20 9–20 NA
Mean no. of virulence
genes
14.4 14.5 13.6 16.8 14.4 NA
a Significant differences are indicated in bold.
b P values (by Fisher’s exact test) are shown where there was a P value of0.05. NA, not applicable.
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(100%), chuA (100%), kpsM II (82%), traT (74%),malX (100%),
usp (100%), and ompT (100%). In contrast, nine virulence genes
were not detected in anyO25b-ST131 isolate; these included papG
I, papG II, sfa/focDE, sfaS, focG, bmaE, gafD, kpsM III, and tsh.
Overall, the 130 O25b-ST131 isolates exhibited relatively high ag-
gregate virulence scores (mean, 14.4; range, 9 to 20), and 106
(82%) satisfied the molecular criteria for ExPEC.
Although the virulence profiles were fairly homogeneous over-
all, four discrete virotypes (labeled arbitrarily as A, B, C, and D)
were resolved based on the presence or absence of four distinctive
virulence genes, including afa FM955459 (specific for an ST131
clone encoding anAfa/Dr adhesin), iroN (catecholate siderophore
receptor), ibeA (invasion of brain endothelium), and sat (secreted
autotransporter toxin). The patterns were as follows: virotype A
(afa FM955459 positive, iroN negative, ibeA negative, sat positive
or negative), virotype B (afa FM955459 negative, iroN positive,
ibeA negative, sat positive or negative), virotype C (afa FM955459
negative, iroN negative, ibeA negative, sat positive), and virotype
D (afa FM955459 negative, iroN positive or negative, ibeA posi-
tive, sat positive or negative). The 130 isolates were distributed
among the four virotypes as follows: A, 29 (22%), B, 40 (31%), C, 41
(32%), andD, 17 (13%),with three isolates remaining unclassified as
to virotype since they lacked all four virotype-defining genes.
Interestingly, the 17 virotype D isolates exhibited significantly
higher virulence scores than did those of other virotypes (mean,
16.8 for D versus 14.4 for A, 14.5 for B, and 13.6 for C) (Table 1).
All four virotypes identified for the Spanish O25b:H4-B2-
ST131 isolates were also represented in 51 of the 52 studied inter-
national O25b:H4-B2-ST131 isolates. Virotype C was by far the
most prevalent (65%), followed by virotypes A (17%), B (10%),
and D (6%).
Insertion of ISL3-like transposase gene in fimB in relation to
virotype. The 130 selected Spanish O25b-ST131 isolates were also
analyzed for an insertion in fimB, similar to the ISL3 transposase
gene observed in E. coli strain Nissle 1917 (GenBank accession no.
AF188737). The fimB insertion was detected in all 113 isolates of
virotypes A, B, andCbut in none of the 17 virotypeD isolates (P
0.001 for all comparisons versus virotype D) (Table 1).
fimH alleles and O25b:H4-B2-ST131 virotypes. fimH se-
quence analysis was done for 40 of the Spanish O25b-ST131 iso-
lates, including 10 each for the four virotypes, which were selected
to include a representation of all virulence gene profiles and PFGE
groups encountered within a particular virotype. Two different
fimH alleles were identified among these 40 isolates. All represen-
tatives of virotypes A, B, and C contained fimH30, whereas all
FIG 1 Distribution ofO25b-ST131 isolates in Spain. TheO25b-ST131 isolateswerewidely distributed across Spain, being recovered from30of the 44 participant
hospitals, including 13 of the 17 autonomous communities of Spain.
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representatives of virotype D contained fimH22 (P 0.001 for all
comparisons versus virotype D).
Virotype versus ESBL variants, CTX-M-15-associated genes,
and antimicrobial resistance. Among the 130 selected O25b:H4-
B2-ST131 isolates, all 69 isolates from virotypes A and B and 63%
(26/41) of the virotype C isolates produced CTX-M-15; however,
no virotype D isolates produced CTX-M-15 (P  0.001 for all
comparisons versus virotype D). In contrast, virotype D isolates
produced CTX-M-9 (5 isolates), CTX-M-14 (6 isolates), SHV-12
(5 isolates), and CTX-M-32 (1 isolate) (Table 2).
As expected, the blaOXA-1 and aac(6=)-Ib-cr genes were associ-
ated with CTX-M-15-producing isolates. These genes were de-
tected in 69% and 100% of virotype A isolates, respectively, 88%
(both genes) of virotype B isolates, and 51% (both genes) of viro-
type C isolates but in 0% of virotype D isolates (P 0.001 for all
comparisons versus virotype D) (Table 2).
Only the 29 virotype A isolates showed an IS26 element within
the terminal inverted repeat of the ISEcp1-like element upstream
of blaCTX-M-15, separating the blaCTX-M-15 allele from its usual pro-
moter, as found in the epidemic ST131 “strain A” that is prevalent
in the United Kingdom (5, 20) (P  0.001 for comparisons with
virotypes B, C, and D) (Table 2).
Different patterns of associated antimicrobial resistances were
detected in relation to virotype. Specifically, ciprofloxacin and to-
bramycin resistancewere significantly associatedwith virotypesA,
B, and C (P  0.001 for all comparisons versus virotype D). In
contrast, virotypes B and Cwere significantly associated with gen-
tamicin resistance (P 0.05 for all comparisons versus virotypes
A and D), and virotype A was significantly associated with trim-
ethoprim-sulfamethoxazole resistance (P 0.05 for all compari-
sons versus virotypes B, C, and D) (Table 2).
PFGE profiles of O25b:H4-B2-ST131 isolates in relation to
virotype. In the PFGE-based dendrogram, 116 of the 130 Spanish
O25b-ST131 isolates were distributed among 4 large virotype-
specific clusters, defined at similarity levels of approximately 72%
(11 virotype D isolates), 76% (28 virotype A isolates), 77% (33
virotype C isolates), and 74% (39 virotype B isolates) (see Fig. S1
in the supplemental material).
A similar clustering of PFGE profiles by virotype was detected
when the 130 Spanish study isolates were compared with the 52
international isolates (see Fig. S2 in the supplemental material).
Four main clusters, each largely virotype specific, comprised 162
of the 182 total isolates. Each of these clusters, defined at similarity
levels of approximately 80% (47 isolates, 40 of virotype B), 78%
(60 isolates, 58 of virotype C), 82% (37 isolates, 36 of virotype A),
and 67% (18 isolates, 16 of virotype D), included isolates from
multiple countries.
In the present study, among 13 international isolates repre-
senting the top four pulsotypes described by Johnson et al. (16),
we found that virotype A corresponded with pulsotype 812, viro-
type B with pulsotype 905, and virotype C with all four pulsotypes
(968, 800, 905, and 812), whereas none of the virotype D isolates
belonged to these top four pulsotypes.
Epidemiological and clinical associations of ESBLEC O25b-
ST131. Associated clinical data were compared for O25b-ST131
and non-O25b-ST131 Spanish ESBLEC isolates (Table 3). In uni-
variate analyses, comparedwith the non-O25b-ST131 isolates, the
O25b-ST131 isolates were significantly associated with older age,
nursing home residents, a health care-related origin, asymptom-
atic bacteriuria, and bacteremia. However, after adjustment for
acquisition type and age by logistic regression analysis, the associ-
ation of O25b-ST131 isolates with bacteremia was not statistically
TABLE 2 ESBL enzymes, genes associated with CTX-M-15 plasmids, and antimicrobial resistance of 130 representatives of O25b:H4-B2-ST131
ESBLEC isolates in relation to their virotypes
Characteristic
No. (%) of isolates by virotypea:
No. (%) of
O25b-ST131
isolatesA B C D
Total no. 29 40 41 17 130
ESBL enzymes
CTX-M-3 0 0 1 (2) 0 1 (0.8)
CTX-M-9 0 0 1 (2) 5 (29) 6 (5)
CTX-M-14 0 0 8 (20) 6 (35) 15 (12)
CTX-M-15 29 (100) 40 (100) 26 (63) 0 96 (74)
CTX-M-32 0 0 4 (10) 1 (6) 5 (4)
CTX-M-103 0 0 1 (2) 0 1(0.8)
SHV-12 0 0 3 (7) 5 (29) 9 (7)
Genes associated with CTX-M-15
blaOXA-1 20 (69) 35 (88) 21 (51) 0 85 (65)
aac(6=)-Ib-cr 29 (100) 35 (88) 21 (51) 0 85 (65)
IS26 element 29 (100) 0 0 0 30 (23)
Antimicrobial resistance
Ciprofloxacin 29 (100) 40 (100) 40 (98) 5 (29) 117 (90)
Gentamicin 0 27 (68) 16 (39) 1 (6) 46(35)
Tobramycin 29 (100) 33 (83) 28 (68) 3 (18) 95 (73)
Trimethoprim-sulfamethoxazole 29 (100) 31 (78) 20 (50) 10 (59) 92 (71)
Amoxicillin-clavulanic acid 10 (34) 6 (15) 9 (22) 0 26 (20)
Fosfomycin 5 (17) 3 (8) 2 (5) 0 11 (9)
a Significant differences are indicated in bold. P values are shown in Results.
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significant (odds ratio [OR], 1.58; 95% confidence interval [CI],
0.91 to 2.75) (P 0.10).
Associations of the four virotypes with demographic data, ac-
quisition type, and type of infection also were explored (Table 4).
Virotype B was significantly associated with older patients and a
lower likelihood of symptomatic infection, specifically urinary
tract infection, but a higher likelihood of respiratory tract infec-
tion. In contrast, virotype C was significantly associated with a
higher likelihood of symptomatic infection, whereas virotype D
was significantly associatedwith younger patients and community
acquisition. Additionally, virotypes A and B were more highly
associated with nursing home residents (17/69 [25%]) than were
virotypes C and D (4/61 [7%]) (P 0.005).
Triplex PCR for virotyping.A triplex PCR based on the detec-
tion of sat, iroN, and ibeAwas designed for virotyping of theO25b:
H4-B2-ST131 isolates. When applied to the present 130 Spanish
and 52 international O25b-ST131 isolates, this assay exhibited
100% specificity and sensitivity (not shown). This assay can be
combined with a previously described triplex PCR (based on de-
tection of the afa operon FM955459, theO25b rfb allele, and the 3=
end of blaCTX-M-15) to establish the virotypes of the O25b-ST131
isolates (Table 5; see also Fig. S3 in the supplemental material).
DISCUSSION
The prevalence and epidemiology of ESBLEC are changing rapidly.
In recent years, ESBLproduction inE. colihas increased significantly,
dueprimarily to the spreadofCTX-Mtypes. In fact, theprevalenceof
ESBLEC strains in Spain increased 8-fold between 2000 and 2006,
from 0.5% to 4% (4). The emergence and dissemination of ESBLEC
have two possible explanations, that it occurs through dissemination
of mobile genetic elements between non-clonally related strains or
through clonal spread. The twomechanismsmight occur simultane-
ously, thereby contributing to the rapid dissemination of ESBLEC
strains. Until a few years ago, most ESBLEC strains were clonally
unrelated; however, recently, theO25b:H4-B2-ST131 intercontinen-
tal E. coli clonal group that produces CTX-M-15 with high virulence
potential has been reported worldwide, representing a major public
health problem (6, 10).
In the present study, 195 (19%) of the 1,021 total ESBLEC
study isolates were of the O25b-ST131 group. The O25b-ST131
isolates were widely distributed across Spain, as they were at 30 of
the 44 participating centers and accounted for up to 52% of
ESBLEC strains per hospital. This contrasts with the 9% preva-
lence of ST131 among the 92 analyzed ESBLEC isolates from a
similar study from 2004 done in 11 Spanish hospitals (7 of which
were included in the present study) (8).More recent studies found
even higher prevalences of O25b-ST131 among ESBLECs in vari-
ous Spanish cities, including Lugo in 2008 (23%) (5) and in 2012
(61%) (27), Barcelona (32% in 2008) (28), Seville (13% in 2010)
(29), and Madrid (21% in 2008) (30). Other countries have also
had high reported prevalences of ST131 among the ESBLEC
strains, including Denmark (38%) (31), Japan (41%) (32), the
United States (47%) (33), and Canada (78%) (34).
The SpanishO25b-ST131 isolates in this study carried not only
CTX-M-15 but also CTX-M-14, SHV-12, CTX-M-9, CTX-M-32,
TABLE 3 Epidemiological and clinical data of patients with
colonization or infection due to ESBLEC O25b:H4-B2-ST131 compared
to those with non-ST131 infection
Patient variable
Value for isolatea:
PeST131 Non-ST131
Total no. 190 818
Male gender (no. [%]) 70 (37) 328 (40)
Median age (IQR) (yr) 75 (68–84) 69 (50–79) 0.01b
No. (%) of pediatric patients
(age 14 yr)
4 (2) 53 (6) 0.01c
Acquisition type (no. [%])
Nosocomial 66 (35) 238 (29)
Health care related 47 (25) 115 (14) 0.001
Community 77 (41) 465 (57) 0.001
Nursing home resident 37 (19) 39 (5) 0.001
Infection site (no. [%])d 136 (72) 651 (80) 0.02
Urinary tract 102 (75) 485 (75)
Soft tissue 16 (12) 71 (11)
Digestive tract 6 (4) 37 (6)
Other types 20 (15) 116 (18)
Bacteremia (primary or
secondary)
22 (16) 56 (9) 0.01
Crude 30-day mortality (no.
[%])d
5 (4) 12 (2)
a Data from 5 patients with ST131 and from 8 patients with non-ST131 isolates were
unavailable. P values were calculated by chi-square test except where otherwise noted.
b Calculated by Mann-Whitney U test.
c Calculated by Fisher’s exact test.
d Only patients with infection were considered.
e P values are shown where P 0.05.
TABLE 4 Association of virotype with epidemiological and clinical data
among 130 O25b:H4-B2-ST131 ESBLEC isolates
Patient variable
Isolates by virotypea:
A B C D
Total no. 29 40 41 17
Male gender (no. [%]) 10 (35) 16 (40) 22 (54) 7 (41)
Age 14 yr (no. [%]) 1 (3) 0 1 (2) 2 (12)
Median age (IQR) (yr) 77 (63–82) 75 (64–83)a 64 (56–79) 60 (34–78)b
Acquisition type (no. [%])
Nosocomial 9 (31) 18 (45) 18 (44) 4 (24)
Health care related 9 (31) 9 (23) 7 (17) 1 (6)
Community 11 (38) 13 (32) 16 (39) 12 (71)c
Nursing home resident 7 (24) 10 (25) 3 (7) 1 (6)
Infection type 22 (85) 21 (57)d 36 (92)e 13 (77)
Urinary tract 20 (69) 13 (33)f 25 (61) 13 (77)
Respiratory tract 0 4 (10)g 1 (2) 0
Digestive tract 0 0 2 (5) 0
Primary bacteremia 0 2 (5) 3 (7) 0
Other types 2 (7) 2 (5) 5 (12) 0
Bacteremia (primary or
secondary)
5 (17) 8 (20) 8 (15) 0
Crude 30-day mortality (no. [%]) 0 6 (15) 4 (10) 1 (6)
Infection-related deaths (no. [%]) 0 3 (8) 1 (2) 0
a P 0.05 (calculated by Mann-Whitney U test). All comparisons other than those
indicated by a footnote have a P value of0.05.
b P 0.03 (calculated by Mann-Whitney U test).
c P 0.03 (calculated by Fisher’s exact test).
d P 0.009.
e P 0.01.
f P 0.0001.
g P 0.03 (calculated by Fisher’s exact test).
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CTX-M-3, and the new ESBL enzyme CTX-M-103 first described
here. Although inmost countries, ST131 is associatedmainly with
CTX-M-15 (6, 33–35), exceptions do occur, such as in Japan,
where O25b-ST131 is frequently associated with CTX-M-14 (36),
or in Ireland, where it is associated with CTX-M-3 (37). In the
present study, we showed that association between E. coli O25b-
ST131 and CTX-M types other than CTX-M-15 was mainly iden-
tified in the isolates with virotype D.
ExPEC isolates have specialized virulence factors enabling
them to colonize host surfaces, injure host tissues, and avoid host
defense systems. Thirteen genes (fimH, F10 papA, iha, sat, iucD,
iutA, fyuA, chuA, kpsM II, traT, malX, usp, and ompT) were de-
tected inmost of the 130 Spanish O25b-ST131 ESBLEC isolates in
this study. In two recent studies, Coelho et al. (28) in Spain and
Johnson et al. (38) in the United States found that these virulence
genes were significantly more prevalent among ST131 than non-
ST131 isolates. Therefore, they might be important in the world-
wide dissemination of E. coliO25b-ST131. Moreover, the present
130 Spanish O25b-ST131 isolates exhibited high virulence scores,
and most qualified molecularly as being ExPEC (23).
After analyzing all the virulence gene profiles together with the
PFGE pulsotypes, we observed that the virotypes we established
corresponded well with the PFGE clusters. Although ST131 iso-
lates share a large set of putative virulence factors, we selected the
four virulence genes (afa FM955459, iroN, ibeA, and sat) that
clearly define the four virotypes within the clonal group O25b-
ST131. Notably, the four virotypes, most prominently virotype C,
were also present in other countries (France, Portugal, Switzer-
land, United States, Canada, Korea, and Lebanon). The XbaI
PFGE dendrogram revealed four major clusters that corre-
sponded closely with the virotypes, suggesting a clonal basis for
the virotypes. Isolates of virotype D exhibited significantly higher
virulence scores, which might explain the association of this viro-
type with younger patients and community-acquired infections.
Like Banerjee et al. (39), we found that patients with O25b-
ST131 isolates were older and more frequently had health care-
associated acquisition (particularly through nursing home resi-
dency) than those with non-O25b-ST131 ESBLEC isolates.
Although the O25b-ST131 isolates were associated with bactere-
mia in univariate analyses, this association was not significant
when age and acquisition type were considered in multivariate
analysis. Chung et al. (40) found that patients with clone ST131
were more likely to have secondary bacteremia than those with
non-ST131 isolates. As has been found in other studies (39–41),
we did not find that O25b-ST131 isolates were associated with
increased mortality. Further studies are needed to more fully as-
sess the clinical implications of the comparatively high virulence
scores and the group B2 background of the O25b-ST131 ESBLEC
isolates. Of note, virotypeDwas linkedwith community-acquired
infections and virotypes A and B with nursing home residents.
In a recent PFGE analysis of 579 ST131 isolates from diverse
years, hosts, and locales, Johnson et al. (16) found that the four
most prevalent pulsotypes (among 170 total) accounted for 46%
of the population and tended to occur inmore recent years, which
is consistent with recent emergence and expansion and implies
greater fitness of these pulsotypes. In the present study, among 13
international isolates representing the top four pulsotypes of
Johnson et al. (16), we found virotypes A, B, and C.
Seven distinct fimH-based putative clonal lineages (H15, H22,
H27, H30, H35, H41, and H49) were found among 352 historical
and recent ST131 isolates obtained primarily from the United
States (42). The H22 subclone was dominant (73%) among the
historical isolates (those from 1967 to 1999), whereas the H30
subclonewas themost prevalent (75%) among the current clinical
isolates (those from 2000 to 2011) and accounted for nearly all
fluoroquinolone-resistant isolates. Interestingly, in the present
study, theH30 subclone accounted for all analyzed SpanishO25b-
ST131 isolates of virotypes A, B, and C, whereas the H22 subclone
accounted for all analyzed virotype D isolates. Consistent with the
association of the H30 ST131 subclone with fluoroquinolone re-
sistance, we found the prevalence of ciprofloxacin resistance to be
significantly higher among the (H30-derived) virotypeA, B, andC
isolates (100%, 100%, and 98%, respectively) than among the
(non-H30) virotype D isolates (29%) (P 0.001).
TABLE 5 Primers included in the two triplex PCR assays used for specific identification of clonal group O25b:H4-B2-ST131 and virotyping
Gene Primer Oligonucleotide sequence (5= to 3=)
Fragment
size (bp)
Annealing
temp (°C) Reference
afa FM955459a AFA-O25F GAGTCACGGCAGTCGCGGCGG 207 55 5
AFA-O25R TTCACCGGCGACCAGCCATCTCC
rfbO25ba rfb.1bis ATACCGACGACGCCGATCTG 300 55 45
rfbO25b.r TGCTATTCATTATGCGCAGC
blaCTX-M-15
a CTX-M-F1 ATAAAACCGGCAGCGGTG 483 55 19
CTX-M-F2 GAATTTTGACGATCGGGG
iroNb IRON-F AAGTCAAAGCAGGGGTTGCCCG 667 60 46
IRON-R GACGCCGACATTAAGACGCAG
satb SAT-F ACTGGCGGACTCATGCTGT 387 60 47
SAT-R AACCCTGTAAGAAGACTGAGC
ibeAb IBEA 10F AGGCAGGTGTGCGCCGCGTAC 170 60 22
IBEA 10R TGGTGCTCCGGCAAACCATGC
a Triplex PCR used for specific identification of O25b-ST131 isolates (5).
b Triplex PCR used for virotyping of O25b-ST131 isolates (developed in this study).
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Diverse explanations have been proposed for the rapid and
successful dissemination of E. coli O25b-ST131 among humans,
including possible transmission through animal contact and food
consumption (43). Mora et al. (44) reported an association of E.
coliO25b-ST131with clinical disease in poultry and identified this
clonal group in retail chicken meat in Spain. In that study, the 19
avian O25b-ST131 isolates (of which 7 produced CTX-M-9) were
of virotype D, defined according to the criteria specified here.
However, in the present study, only 2 of the 17 Spanish human
isolates of virotype D (isolates 16.30 and 16.31; fimH, iucD, iroN,
kpsMII-K1, iss, traT, ibeA,malX, usp, and SHV-12) and the 2 avian
virotype D isolates from the United States (isolates CD285 and
CD287; fimH, iucD, iroN, kpsMII-K1, iss, traT, ibeA, malX, usp,
and tsh) showed virulence gene profiles that were highly similar to
those of the Spanish avian isolates (44).
In conclusion, we found a high prevalence of E. coli O25b:
H4-B2-ST131 among (mostly CTX-M-15-producing) ESBLEC
isolates from hospitals across Spain in 2006. We newly defined
four main virulence gene profile variants within ST131, which
we termed virotypes A to D, and showed these to be prevalent
also among isolates from other countries. The four ST131 vi-
rotypes, which appeared to represent clonal variants within
ST131, exhibited distinctive distributions and clinical and ep-
idemiological associations. Future studies of the conventional
and molecular epidemiology of ST131 should address relevant
within-ST divisions, including fimH-based subclones and viro-
types. Such studies should improve our understanding of the
basis for the worldwide dissemination and emergence of the E.
coli ST131 clonal group.
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